Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis
Clinical trial NCT06144424 · COMPLETED
Trial details
- NCT number
- NCT06144424
- Sponsor
- Escient Pharmaceuticals, Inc
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-25
- Primary completion
- 2024-07-31
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.